Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016 | Zendy

Sean Dickson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016

Author(s) -

Sean Dickson

Publication year - 2019

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2019.18366

Subject(s) - medicaid , copayment , prescription drug , medical prescription , business , incentive , product (mathematics) , market share , generic drug , actuarial science , health care , public economics , marketing , medicine , drug , economics , pharmacology , health insurance , economic growth , geometry , mathematics , microeconomics

Annual spending on retail and nonretail prescription drugs exceeds $450 billion and is projected to outpace growth in all other national health expenditure categories over the next decade. Evergreened reformulations of drugs, defined here as extended-release or other reformulations that came to market more than 2 years after initial approval of the immediate-release product, increase drug spending and delay patient access to extended-release formulations. Reforming drug approval incentives may encourage earlier introduction of extended-release formulations, hastening generic adoption and patient access.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research